Astria Therapeutics, Inc.
ATXS
$7.49
-$0.04-0.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.72% | -2.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.18% | 25.02% | |||
| Operating Income | 3.18% | -25.02% | |||
| Income Before Tax | 1.95% | -31.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.95% | -31.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.95% | -31.54% | |||
| EBIT | 3.18% | -25.02% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 1.94% | -31.56% | |||
| Normalized Basic EPS | 1.95% | -31.55% | |||
| EPS Diluted | 1.94% | -31.56% | |||
| Normalized Diluted EPS | 1.95% | -31.55% | |||
| Average Basic Shares Outstanding | 0.00% | -0.02% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||